A new study reports that low-dose Campath (alemtuzumab) not only treats patients with Leukemic cutaneous T-cell lymphoma (L-CTCL) but does so without increasing their risk of infections.
Rachael A. Clark, MD, PhD, BWH assistant professor of dermatology and associate dermatologist and Thomas Kupper, MD, BWH Department of Dermatology chairman and their colleagues have reported the new study. The study was electronically published on January 18, 2012 in Science Translational Medicine.
Leukemic cutaneous T-cell lymphoma is a leukemia arising from T-cells, a type of white blood cell. This cancer can involve the skin and other organs, and patients often die within three years.
"We noticed that our patients were not getting infections, and we looked in the skin. We saw healthy T-cells remaining there despite the fact that there were no T-cells in the blood," said Clark. "We used to believe that most T-cells responsible for protecting against infection were in the bloodstream. But we now realize that highly protective T-cells also inhabit tissues such as the skin, lungs and gastrointestinal tract. It is these tissue resident T-cells that are critical in protecting us from infection on a day-to-day basis."
By showing that Campath kills circulating T-cells, including the cancerous T-cells, but spares tissue resident T-cells, Clark and Kupper have shown that Campath effectively treats L-CTCL while sparing normal immunity. Their findings are also the first demonstration in human beings that tissue resident T-cells provide frontline immune protection of the skin.
"We're very grateful to our patients for entrusting us with their care and for teaching us important lessons about the immune system." said Clark.
In a companion piece, Mark Davis, PhD, Stanford University School of Medicine, called the work a "translational tour de force."